News
July 15, 2015County Legislature Unanimously Passes Resolution in Support of Fiorello Pharmaceuticals’ Plan for State-of-the-Art Medical Marijuana Manufacturing Facility in Glenville
Fiorello Pharmaceuticals, Inc., an applicant for one of five medical marijuana licenses to be awarded by the New York State Department of Health, today announced that the Schenectady County Legislature has unanimously voted in favor of the Company’s plan to build a cutting-edge medical marijuana manufacturing facility in Glenville, joining business leaders in support of the company’s proposed effort.
The Schenectady County Legislature today passed a resolution supporting Fiorello’s proposal to invest $10 million in construction upgrades in a state-of-the-art medical marijuana manufacturing facility at the Glenville Business and Technology Park. The Legislature, which received a full briefing on Fiorello’s plans to manufacture medicinal cannabis for New Yorkers suffering from life-threatening and debilitating diseases, unanimously voted in favor of the resolution.
“We thank the Schenectady County Legislature for its support of our plan to operate an industry-leading medical marijuana manufacturing facility in the Glenville Business and Technology Park,” said Ari Hoffnung, Founder and CEO, Fiorello Pharmaceuticals. “We are proud to be welcomed with open arms by such a vibrant and fast-growing community. The Legislature’s resolution is further proof that Fiorello’s commitment to bringing over 100 high-paying, permanent jobs to the Capital Region is positive for the local economy. We hope to offer the hard-working people across the region the opportunity to work in a cutting-edge industry that will improve the lives of patients suffering from cancer, epilepsy, and other debilitating diseases.”
The resolution accompanies an endorsement from the Chamber of Schenectady County celebrating Fiorello’s plan to cultivate medicinal cannabis at the Glenville Business and Technology Park. The Chamber of Schenectady County President Charles Steiner, CCE, called Fiorello a “socially responsible business,” adding that he would proudly welcome the company to the community if Fiorello is awarded a license by the New York State Department of Health.
“The Chamber believes that Fiorello Pharmaceuticals’ proposal would have a tremendous economic impact on Schenectady County and the Capital Region beyond the $10 million investment in construction and the creation of 100 good-paying manufacturing jobs,” said Charles Steiner, CCE, President, The Chamber of Schenectady County, in a letter to Fiorello Pharmaceuticals CEO and Founder Ari Hoffnung. “We are grateful that you are committed to investing $1 million in the Capital Region for research. The Chamber of Schenectady County fully supports Fiorello Pharmaceuticals’ proposal to operate a medical marijuana manufacturing facility at the Glenville Business and Technology Park.”
“The Capital Region business community has been extremely supportive of our efforts, and we thank Mr. Steiner and all Chamber of Schenectady County members for supporting our company as we seek a medical marijuana license in New York State,” said Hoffnung. “It was clear in our conversations with the Chamber and other business leaders that we collectively share a desire to extend the region’s national lead in pharmaceutical and scientific advancement. We hope to join the growing and distinguished companies that have helped make the Capital Region such an attractive destination for doing business.”
Fiorello Pharmaceuticals previously announced plans to invest $10 million in a state-of-the-art medical marijuana manufacturing facility in Glenville, NY. Fiorello Pharmaceuticals will create more than 100 management, research, and technology jobs in the Capital Region, in addition to jobs in its dispensaries across New York State. Fiorello’s four dispensaries will be operated by licensed pharmacists who will dispense the medicine to New York State-certified patients.
Fiorello has earmarked $1 million in grants to Capital Region institutions as part of a $5 million commitment to medical marijuana scientific and clinical research. The research commitment is the largest sum ever offered in the medical marijuana industry.
